FindTrial
Sign In

Evaluation of the combined value of mesalazine in the treatment of ulcerative colitis with vedolizumab

Evaluation of the combined value of mesalazine in the treatment of ulcerative colitis with vedolizumab

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101494
Enrollment
Unknown
Registered
2025-04-25
Start date
2024-04-15
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Vedexlizumab group:None
Verdexlizumab combined with mesalazine in the 3-month group:None
Verdexlizumab combined with mesalazine in the 1-year group:None

Sponsors

Northern Jiangsu People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with a diagnosis of UC; 2.18-80 years; 3.Indications for 5-ASA or vedolizumab; 4.No prior use of biologics.

Exclusion criteria

Exclusion criteria: 1.Patients discontinuing therapy due to allergy to 5-ASA or vedolizumab; 2.Comorbidities with other intestinal disorders; 3.Patients with psychiatric disorders; 4.Pregnant women.

Design outcomes

Primary

MeasureTime frame
Biological mitigation rate;Endoscopic response or remission rate;Clinical response or remission rate;—

Secondary

MeasureTime frame
Adverse event rate;—

Countries

China

Contacts

Public ContactJie Chen

Northern Jiangsu People’s Hospital

Jiechendoctor@163.com+86 180 5106 0571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026